脑卒中是严重危害我国国民健康的主要疾病。目前的研究认为糖尿病是脑卒中发生的重要的危险因素之一。前期研究认为糖尿病使得缺血性卒中患者侧枝循环建立较差，可能是合并糖尿病的脑卒中患者预后差的重要原因之一。二肽基肽酶-4（dipeptidylpeptidase-4，DPP-4）抑制剂是新近发现的优良降糖药物，此外还具有降糖以外的心脑器官保护作用。前期研究多集中在神经元保护方面，对于脑侧枝循环建立和脑微血管内皮细胞保护方面的研究较少。去乙酰化酶1（sirtuin1，SIRT1）是广泛存在于中枢神经系统的代谢调节酶，在神经保护研究中有着重要作用。但是DPP-4的神经保护机制是否也涉及到SIRT1的参与，目前没有相关报道。基于以上我们推测应用DPP-4抑制剂对糖尿病缺血性卒中细胞模型进行治疗，可能会增强SIRT1活性，并可促进血管内皮细胞的生成，进一步明确DPP-4神经保护机制，为新药研发开拓新途径。

Stroke is a major disease which cause serious damage to China's national health. The present study indicated that diabetes is one of the important risk factors for stroke. Early research suggested that diabetes makes poor collateral circulation in patients with ischemic stroke,which may be one of the important causes of poor prognosis with stroke patients. Dipeptidylpeptidase - 4(DPP - 4) inhibitors are newly discovered good oral glucose-lowering drugs, moreover also has the cardio-cerebral organ protection. Previous research focus on the protection of neurons.But the data is less for cerebral collateral circulation establishment and protection of cerebral microvascular endothelial cells . Acetylation enzyme 1 (SIRT1) is widespread in the central nervous system and plays an important role in the study of neuroprotection. But there is no related reports for the DPP - 4 nerve protection mechanism involving the participation of SIRT1 . So we.speculated that the application of DPP - 4 inhibitors for the treatment of diabetes cell model of ischemic stroke, may enhance the SIRT1 activity and can promote the production of vascular endothelial cells.Through our study, we would like to further define DPP - 4 nerve protection mechanism, and to explore new ways for new neuroprotection drugs.